This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. SCYX, PRLD, ELYM, LTRN, RNTX, IRD, PEPG, FBRX, XLO, and CNTBShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include SCYNEXIS (SCYX), Prelude Therapeutics (PRLD), Eliem Therapeutics (ELYM), Lantern Pharma (LTRN), Rein Therapeutics (RNTX), Opus Genetics (IRD), PepGen (PEPG), Forte Biosciences (FBRX), Xilio Therapeutics (XLO), and Connect Biopharma (CNTB). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. SCYNEXIS Prelude Therapeutics Eliem Therapeutics Lantern Pharma Rein Therapeutics Opus Genetics PepGen Forte Biosciences Xilio Therapeutics Connect Biopharma SCYNEXIS (NASDAQ:SCYX) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings. Which has better earnings & valuation, SCYX or RXII? SCYNEXIS has higher revenue and earnings than RXi Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$3.75M9.41$67.04M-$0.44-2.06RXi Pharmaceuticals$10K1,182.60-$12.45M-$4.20-0.64 Does the media favor SCYX or RXII? In the previous week, SCYNEXIS's average media sentiment score of 0.88 beat RXi Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Positive RXi Pharmaceuticals Neutral Do institutionals and insiders have more ownership in SCYX or RXII? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SCYX or RXII more profitable? SCYNEXIS has a net margin of -425.41% compared to RXi Pharmaceuticals' net margin of -4,990.20%. SCYNEXIS's return on equity of -66.21% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-425.41% -66.21% -38.84% RXi Pharmaceuticals -4,990.20%-412.15%-179.54% Does the MarketBeat Community prefer SCYX or RXII? SCYNEXIS received 313 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. Likewise, 69.85% of users gave SCYNEXIS an outperform vote while only 68.09% of users gave RXi Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSCYNEXISOutperform Votes50569.85% Underperform Votes21830.15% RXi PharmaceuticalsOutperform Votes19268.09% Underperform Votes9031.91% Which has more risk & volatility, SCYX or RXII? SCYNEXIS has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. SummarySCYNEXIS beats RXi Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Remove Ads Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.83M$6.44B$5.28B$7.34BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-0.646.8321.6917.75Price / Sales1,182.60230.62378.4897.65Price / CashN/A65.6738.1534.64Price / Book3.515.906.433.98Net Income-$12.45M$142.50M$3.20B$247.33M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.70+11.1%N/A+271.4%$11.83M$10,000.00-0.64N/AGap DownSCYXSCYNEXIS0.3124 of 5 stars$0.99+13.4%N/A-35.3%$38.47M$3.75M-1.3360Gap UpPRLDPrelude Therapeutics2.5236 of 5 stars$0.69-2.0%$4.00+476.4%-84.3%$38.28M$7M-0.39120Gap UpELYMEliem TherapeuticsN/A$1.28+10.3%N/A-70.2%$38.08MN/A-2.429LTRNLantern Pharma2.1939 of 5 stars$3.53+10.0%$25.00+608.2%-41.8%$38.07MN/A-1.9820Positive NewsGap UpRNTXRein TherapeuticsN/A$1.66-2.9%N/AN/A$37.61MN/A-0.539News CoverageGap DownIRDOpus Genetics1.992 of 5 stars$0.82+16.1%$7.33+791.5%N/A$37.42M$10.99M-0.7514PEPGPepGen2.534 of 5 stars$1.10-2.7%$10.33+839.4%-90.2%$36.94MN/A-0.3730Gap DownFBRXForte Biosciences2.7848 of 5 stars$5.59+6.5%$32.50+481.4%+24,817.6%$36.79MN/A-0.345Options VolumeGap UpXLOXilio Therapeutics2.6541 of 5 stars$0.71+0.8%$4.00+459.9%-41.7%$36.71M$6.34M-0.4270Positive NewsCNTBConnect Biopharma3.1472 of 5 stars$0.65+4.1%$8.00+1,129.1%-51.2%$36.03M$24.12M0.00110Short Interest ↓High Trading Volume Remove Ads Related Companies and Tools Related Companies SCYX Alternatives PRLD Alternatives ELYM Alternatives LTRN Alternatives RNTX Alternatives IRD Alternatives PEPG Alternatives FBRX Alternatives XLO Alternatives CNTB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXII Stock Free RXII Stock Alerts